A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)

Trial Profile

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs ICO-007 (Primary) ; Ranibizumab
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms iDEAL
  • Most Recent Events

    • 28 Nov 2014 Status changed from active, no longer recruiting to discontinued, according to an iCo Therapeutics media release.
    • 09 Jun 2014 According to an iCo Therapeutics media release, final dosing of iCo-007 injections is complete and last patient follow-up visit at 12 month is expected to be in June 2014. Safety reports and secondary endpoints data are expected in Q4 2014.
    • 09 Jun 2014 Results (Top-line primary endpoint data) published in an iCo Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top